Myasthenic Crisis: Analysis of Predisposing factors, Clinical features, complications and treatment Outcome

Myasthenia gravis is a neuro-muscular junction disorder characterized by skeletal muscle weakness and fatiguability. It is due to a decrease in the number of available acetylcholine receptors at the neuromuscular junction as a result of antibody mediated autoimmune attack. Weakness of muscles may involve cranial and somatic musculatures. Weakness resembling myasthenia gravis may occur in other conditions as a result of drug, endocrine disease of thyroid, certain malignancies, bacterial toxins and also by non-autoimmune mechanisms involving the neuromuscular junction. The weakness may involve all the skeletal muscles of the body but the distribution of weakness has a characteristic pattern and there is a diurnal variation of symptoms. If the weakness of respiratory muscles becomes so severe as to require respiratory assistance, then it is called myasthenic crisis. The myasthenia may be generalized one involving all the groups of muscles or it may involve the extra ocular muscles and facial muscles. Sometimes the bulbar muscles alone may be involved and the condition is called bulbar myasthenia gravis. In some of the patients, (anti-AchR) Acetyl choline receptor antibodies may be positive and in some it will be negative. In some of the patients, anti-muscle specific tyrosine kinase antibodies will be positive and negative in some of the patients. CONCLUSION : 1. In our study, the commonest age group of presentation of myasthenic crisis is the fourth decade (36%). 2. Male predominance (56%) was noted in our study. 3. The most common predisposing factor is the respiratory infection (28%). 4. In three patients, the presenting symptoms of myasthenia gravis was crisis itself. 5. The mean duration of onset of myasthenia gravis to the onset of crisis was 439.36 days. 6. The duration of myasthenia gravis does not influence the occurrence of myasthenic crisis. 7. Our patients presented with predominant bulbar symptoms with respiratory distress. 8. Ventilator associated pneumonia and other respiratory complications influenced the outcome of treatment of myasthenic crisis. 9. 32% of thymectomised patients had myasthenic crisis. 10. Higher age is a risk factor and younger age is a favourable factor for good outcome. 11. Duration of myasthenia gravis have no role on the outcome of crisis. 12. The better survival rate in ventilated patients outweigh the preventable ventilator related complications

Myasthenia gravis

Abstract Not Provided

Myasthenia gravis

Abstract Not Provided

Anti-acetylcholine receptor antibodies and myasthenia gravis

SIGLEAvailable from British Library Document Supply Centre- DSC:DX171436 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

Le malattie infiammatorie immuno-mediate (IMID) di interesse internistico: fisiopatologia, aspetti clinici e prospettive di terapia

Le IMID: inquadramento introduttivo A. Fontanella, G. Uomo Infiammazione e IMID T. d’Errico, M. Laccetti Malattia IgG4-relata C. Mastrobuoni, G. Uomo IMID in ematologia F. Rezzonico, A. Mazzone IMID in reumatologia A. Parisi, R. Buono, R. Russo, G. Uomo IMIDs in neurologia G.T. Maniscalco, C. Florio IMID in diabetologia R. Nicosia, C. Ricordi IMIDs in endocrinologia M.R. Poggiano, V. Nuzzo Malattie infiammatorie intestinali M. Salice, L. Calandrini, C. Praticò, M. Mazza, A. Calafiore, G. Carini, C. Calabrese, A. Belluzzi, F. Rizzello, P. Gionchetti, M. Campieri La malattia celiaca nel terzo millennio: nuove prospettive su patogenesi, clinica, diagnosi e terapia G. Caio, F. Giancola, R. De Giorgio, U. Volta Malattie epato-biliari autoimmuni M. Visconti, L. Fontanella, G. Marino Marsilia Pancreatiti autoimmuni P.G. Rabitti, R. Boni IMID e tumori F. Gallucci La sindrome infiammatoria da ricostruzione immune I. Ronga, G. Uomo Le malattie autoinfiammatorie M. Gattorno, A. Brucato Il rischio cardio-vascolare nelle IMIDs A. Fontanella, P. Gnerre, R. Nardi Quale ruolo degli inibitori delle PCSK9 in Medicina Interna nella prevenzione cardio-vascolare in alternativa alle terapie tradizionali? P. Gnerre, P. Zuccheri, M. Campanini, G. Pinna, R. Nardi Trombo-embolismo venoso e malattie autoimmuni sistemiche A. Fontanella, P. Gnerre, R. Nardi IMID nell’anziano: cenni sul trattamento M. Masina Farmaci biosimilari e farmaci innovativi in reumatologia: quale futuro? M. Todoerti, C. Montecucc